Advertisement
Advertisement



HIV/AIDS NEWSROOM

Snapshot From IAS 2017

British Columbia Researchers Study HIV Treatment Interruptions and Their Consequences

Darunavir/Cobicistat/FTC/TAF: 24-Week Interim Results From Phase 3 Switch Study

Phase 3 Results With Bictegravir -- A New Integrase Inhibitor Combined With FTC/TAF

Isentress HD in Clinical Trials

Scientists Hone in on the Best Way to Expose HIV Hidden in the Viral Reservoir, a Crucial Step Toward an Eventual Cure

This Week in HIV Research: Effect of Viral Load Perception on Sex, and HIV Prevention Options Needed in U.S. Prisons

Maintaining HIV Service Organizations Effectiveness in the New Prevention and Treatment Landscape

IAS and WHO Identify the Most Critical Research Needs for Infants, Children and Adolescents Living With HIV

Mystifying Cochrane Library Review on HCV Therapy Elicits Strong Response from IDSA

Know Your Drugs and Classes of HCV Treatment

Isentress HD: A New Once-Daily Formulation of Raltegravir Approved in Canada

Declining Funding and Shrinking Donor Base Imperils Continued Success of HIV Prevention

FDA Approves Vosevi for Hepatitis C

Who's Most at Risk of Getting Kaposi Sarcoma? New Research Gives Insights

Depression and Anxiety Not Barriers to HCV Treatment Success



Advertisement